Biontech investors are disillusioned: After the run on the share, the price is currently far from its all-time high. Are the new study data on an anti-cancer drug the salvation?
Biontech, known for developing the first vaccine against Corona approved in the EU, is researching the next miracle cure: The company recently published the results of a study on pancreatic cancer. A personalized drug based on mRNA technology was used: BNT122. Biontech tested the drug on patients who suffer from pancreatic cancer and have already had an operation.
They show that BNT122 caused an immune reaction in half of the patients – eight out of 16 participants. In particular, an increase in active T cells was noticeable. Patients who responded positively to the drug experienced a longer period of time without cancer recurrence.
Source: Stern
